FINANCE ROUNDUP: Six VC financings and a royalty deal
This article was originally published in Scrip
Executive Summary
Biotechnology companies and their investors came back from summer break with a slew of venture capital funding rounds and a royalty deal, although it remains to be seen how many early-stage firms will remain financially independent with large biotech and pharmaceutical companies raising massive stockpiles of cash.
You may also be interested in...
IPO Update: Haircuts Needed To Price Biotech Offerings
The two drug developers that managed to launch initial public offerings in the US during the past two weeks had to accept rough haircuts in order to get investors to buy their newly issued stock.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.